5-Amino-1MQ for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

5-Amino-1MQ for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

5-Amino-1MQ is a laboratory-made compound sold outside approved channels and used in longevity and weight-management clinics for fat loss and age-related muscle decline. In mice it lowered fat mass without reducing food intake, improved blood sugar handling, cut liver fat, and raised grip strength in old animals. The compound itself has never been given to a person; the safety picture is blank rather than unfavourable. (Full Review)

Protocol

Dose
50-150 mg orally once daily
Most commonly 100 mg; a smaller number of clinics use 2.5-5 mg subcutaneously
Cycle length
8-12 weeks
Standard clinic protocol; neither the fixed-dose nor the allometric approach rests on human pharmacokinetic data
Timing
Morning, with food
Split dosing, for example 50 mg twice daily, is the more defensible reading of the rodent pharmacokinetics
Time to effect
Grip strength
8 weeks
Rodent strength studies ran eight weeks; no human time course exists
Metabolic endpoints
28 days
Length of the rodent glucose tolerance and insulin sensitivity studies
First reassessment
8-12 weeks
Clinic protocols set the first reassessment at 8-12 weeks rather than earlier

Benefits

Contraindications
  • Pregnancy and lactation, or planning conception
  • Anyone under 18 years of age
  • Estimated glomerular filtration rate below 30 mL/min/1.73 m² (severe kidney impairment)
  • Child-Pugh Class B or C liver disease (moderate to severe cirrhosis)
  • Parkinson disease or any other parkinsonian syndrome, and first-degree relatives
  • Active malignancy or treatment within the last 12 months
  • Untreated vitamin B12 deficiency or homocystinuria, or baseline homocysteine above 15 µmol/L
    •
Key Interactions
  • Organic cation transporter substrates (metformin, dolutegravir, procainamide)
  • Organic cation transporter inhibitors (cimetidine, trimethoprim, ranolazine)
  • Over-the-counter high-dose nicotinamide or niacin
  • NAD+ precursor supplements (nicotinamide riboside, nicotinamide mononucleotide)
  • Methyl-donor supplements (S-adenosylmethionine, trimethylglycine, methylfolate, methylcobalamin)
  • Glucose- and weight-lowering agents (GLP-1 receptor agonists such as semaglutide, metformin, berberine)
  • Other interventions (caloric restriction, resistance or endurance exercise)
    •

Risk & Side Effects

  • Low: Higher Baseline Liver Enzymes
    •
  • Speculative: Impaired Embryo Implantation; Unknown Effect on Whole-Body Methylation Balance; Loss of 1-methylnicotinamide Signalling (conflicted); Reduced Neuronal Self-Clearance and Shortened Lifespan on Enzyme Loss; Shared Chemical Class With Dopaminergic Neurotoxins; Unverified Product Identity, Purity, and Dose; Nausea, Headache, and Sleep Disturbance; Absent Reproductive and Chronic Toxicology Data
    •

Monitoring

Marker Target Why
Body fat percentage 10-20% (men), 18-28% (women) Primary endpoint the animal work moved
Fasting insulin 2-5 µIU/mL Earliest marker of the insulin-sensitivity claim
HOMA-IR Below 1.5 Composite index of insulin resistance
HbA1c 4.8-5.4% Confirms any glucose change is sustained
ALT and AST Below 25 U/L (men), below 20 U/L (women) Liver is where the evidence is most conflicted
Homocysteine Below 8 µmol/L Direct readout of the methyl cycle the drug perturbs
Vitamin B12 and folate B12 above 500 pg/mL; folate 10-25 ng/mL Methyl-cycle inputs that determine tolerance of the perturbation
ApoB Below 80 mg/dL Lipid effect is conflicted in both directions
eGFR and creatinine eGFR above 90 mL/min/1.73 m² Clearance route for a charged cation
hs-CRP Below 0.5 mg/L Tracks the inflammatory component of the metabolic picture
Grip strength No established target; 5% rise over 12 weeks from own baseline Objective functional anchor for the muscle claim
Plasma 1-methylnicotinamide No established target; a fall indicates target engagement Only available marker that the enzyme is actually inhibited

Cadence: Baseline before the first dose; week 4 for liver enzymes and homocysteine only; full repeat at week 12 at the end of a cycle; then the full panel every six months while cycling

Qualitative Assessment

  • Sleep onset latency and number of night awakenings, given the reported sleep disturbance
  • Daytime energy and perceived exertion during habitual training sessions
  • Appetite, which should be unchanged, since appetite suppression would point to something other than the intended mechanism
  • Gastrointestinal comfort in the first two weeks, the window in which nausea is reported
  • Any new tremor, movement slowing, or handwriting change, checked deliberately rather than incidentally
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.